White Pine Capital LLC Sells 5,079 Shares of InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU)

White Pine Capital LLC reduced its position in shares of InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) by 3.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,302 shares of the medical instruments supplier’s stock after selling 5,079 shares during the period. White Pine Capital LLC’s holdings in InfuSystem were worth $1,574,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in INFU. Barclays PLC bought a new position in InfuSystem during the 2nd quarter valued at about $35,000. WINTON GROUP Ltd bought a new position in shares of InfuSystem in the third quarter worth about $101,000. Citigroup Inc. raised its stake in shares of InfuSystem by 124.1% in the third quarter. Citigroup Inc. now owns 50,640 shares of the medical instruments supplier’s stock worth $488,000 after acquiring an additional 28,038 shares during the last quarter. First Eagle Investment Management LLC raised its stake in shares of InfuSystem by 29.6% in the third quarter. First Eagle Investment Management LLC now owns 468,400 shares of the medical instruments supplier’s stock worth $4,515,000 after acquiring an additional 107,001 shares during the last quarter. Finally, Heartland Advisors Inc. raised its stake in shares of InfuSystem by 17.6% in the third quarter. Heartland Advisors Inc. now owns 500,000 shares of the medical instruments supplier’s stock worth $4,820,000 after acquiring an additional 75,000 shares during the last quarter. 71.13% of the stock is owned by institutional investors.

InfuSystem Trading Up 6.7 %

Shares of NYSEAMERICAN INFU traded up $0.51 during trading on Friday, reaching $8.12. The company had a trading volume of 27,842 shares, compared to its average volume of 48,498. InfuSystem Holdings, Inc. has a 52 week low of $7.57 and a 52 week high of $11.44. The company has a market cap of $172.63 million, a PE ratio of 270.76 and a beta of 1.24. The company has a current ratio of 1.95, a quick ratio of 1.54 and a debt-to-equity ratio of 0.56.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 17th.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.